{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:56:59Z","timestamp":1781643419791,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic steatosis, characterized by excessive triglyceride accumulation within hepatocytes, is the central feature of non-alcoholic fatty liver disease (NAFLD). This spectrum encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), progressive fibrosis, and cirrhosis. NAFLD pathogenesis involves an intricate interplay between nutritional factors, metabolic dysregulation, and genetic predisposition. Evidence suggests hyperuricemia is an independent risk factor for NAFLD, with elevated serum uric acid (SUA) levels associated with increased steatosis severity and fibrosis advancement. This study investigated the association between SUA levels and liver involvement\u2014specifically ultrasound-assessed steatosis grading and elastography-measured liver stiffness\u2014in patients with NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study enrolled 70 patients aged \u226518 years with ultrasound-diagnosed NAFLD (Group I) and 70 age-, sex-, and residence-matched healthy controls (Group II). Participants were recruited from Minia University Liver Hospital between March 2022 and February 2023. Exclusion criteria included excessive alcohol consumption, viral or autoimmune hepatitis, established cirrhosis, and medications affecting uric acid metabolism. The primary outcome was presence of NAFLD. Evaluations comprised detailed medical history, anthropometric measurements, laboratory testing (including SUA), abdominal ultrasonography for steatosis grading, and two-dimensional shear wave elastography for liver stiffness assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hyperuricemia prevalence reached 55.7% (\n                      <jats:italic>n<\/jats:italic>\n                      =39) among NAFLD patients compared to 0% in controls (\n                      <jats:italic>p<\/jats:italic>\n                      =0.001). Mean SUA concentrations were significantly elevated in the NAFLD group versus controls (5.98 \u00b1 1.9 mg\/dL vs. 4.34 \u00b1 0.7 mg\/dL,\n                      <jats:italic>p<\/jats:italic>\n                      =0.001). A significant association emerged between hyperuricemia and hepatic steatosis grades (\n                      <jats:italic>p<\/jats:italic>\n                      =0.032). Multivariate logistic regression identified SUA as independently associated with NAFLD after adjustment for confounders (Adjusted OR 1.45; 95% CI: 1.12\u20131.88,\n                      <jats:italic>p<\/jats:italic>\n                      =0.005 per 1 mg\/dL increment), alongside BMI, waist circumference, triglycerides, and creatinine. Receiver operating characteristic (ROC) analysis demonstrated an optimal 5.3 mg\/dL SUA cut-off for NAFLD discrimination (AUC 0.74, 64% sensitivity, 94% specificity,\n                      <jats:italic>p<\/jats:italic>\n                      =0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated SUA levels were consistently associated with NAFLD presence, steatosis severity, and increased liver stiffness. The 5.3 mg\/dL threshold warrants further validation. Notable limitations include single-center recruitment potentially limiting generalizability, a cross-sectional design precluding temporal relationship and causality determination, and the possibility of residual confounding from unmeasured variables.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04655-2","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:57:21Z","timestamp":1773910641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-6271","authenticated-orcid":false,"given":"Haitham A.","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Mohamed","family":"Abd Elghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdelhakeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnaa M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nady","family":"Semeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa M","family":"Abdelhalim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa M","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa H","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar M","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdelazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"1","key":"4655_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000282080","volume":"28","author":"S Bellentani","year":"2010","unstructured":"Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155\u201361.","journal-title":"Dig Dis"},{"issue":"16","key":"4655_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"4655_CR3","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/hep.23594","volume":"51","author":"BQ Starley","year":"2010","unstructured":"Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820\u201332.","journal-title":"Hepatology"},{"issue":"6","key":"4655_CR4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1440-1746.2007.04952.x","volume":"22","author":"JG Fan","year":"2007","unstructured":"Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia\u2013Pacific? J Gastroenterol Hepatol. 2007;22(6):794\u2013800.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4655_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2008.11.021","volume":"50","author":"Y Li","year":"2009","unstructured":"Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50(5):1029\u201334.","journal-title":"J Hepatol"},{"issue":"6","key":"4655_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/03009741003742797","volume":"39","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, Yu KH, Luo SF, Chiu CT, Ko YS, Hwang JS, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol. 2010;39(6):466\u201371.","journal-title":"Scand J Rheumatol"},{"key":"4655_CR7","doi-asserted-by":"publisher","first-page":"116539","DOI":"10.1016\/j.bone.2022.116539","volume":"164","author":"A Al Saedi","year":"2022","unstructured":"Al Saedi A, Debruin DA, Hayes A, Hamrick M. Lipid metabolism in sarcopenia. Bone. 2022;164:116539.","journal-title":"Bone"},{"issue":"1","key":"4655_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4093\/dmj.2022.0081","volume":"47","author":"HS Kim","year":"2023","unstructured":"Kim HS, Lee J, Kim EH, Lee MJ, Bae IY, Lee WJ, et al. Association of myosteatosis with nonalcoholic fatty liver disease, severity, and liver fibrosis using visual muscular quality map in computed tomography. Diabetes Metab J. 2023;47(1):104.","journal-title":"Diabetes Metab J"},{"issue":"10","key":"4655_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/lt.23495","volume":"18","author":"P Tandon","year":"2012","unstructured":"Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18(10):1209\u201316.","journal-title":"Liver Transpl"},{"issue":"2","key":"4655_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/CCLM.2010.037","volume":"48","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010;48(2):175\u201380.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"4655_CR11","first-page":"12","volume":"73","author":"T Yamada","year":"2010","unstructured":"Yamada T, Suzuki S, Fukatsu M, Wada T, Yoshida T, Joh T. Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup. Acta Gastroenterol Belg. 2010;73(1):12\u20137.","journal-title":"Acta Gastroenterol Belg"},{"issue":"2","key":"4655_CR12","first-page":"125","volume":"20","author":"MA Hediger","year":"2005","unstructured":"Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiol (Bethesda). 2005;20(2):125\u201333.","journal-title":"Physiol (Bethesda)"},{"issue":"17","key":"4655_CR13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.282.17.1659","volume":"282","author":"H Cortez-Pinto","year":"1999","unstructured":"Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282(17):1659\u201364.","journal-title":"JAMA"},{"issue":"9","key":"4655_CR14","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1681\/ASN.2007121304","volume":"19","author":"O Glushakova","year":"2008","unstructured":"Glushakova O, Kosugi T, Roncal C, Mu W, Heinig M, Cirillo P, et al. Fructose induces the inflammatory molecule ICAM-1 in endothelial cells. J Am Soc Nephrol. 2008;19(9):1712\u201320.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4655_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1681\/ASN.2008060576","volume":"20","author":"P Cirillo","year":"2009","unstructured":"Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KM, Gesualdo L, et al. Ketohexokinase-dependent metabolism of Fructose induces Proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol. 2009;20(3):545\u201353.","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"4655_CR16","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.3390\/nu15143097","volume":"15","author":"S Zhou","year":"2023","unstructured":"Zhou S, Wu L, Si H, Shen B. Longitudinal association between uric acid and incident sarcopenia. Nutrients. 2023;15(14):3097.","journal-title":"Nutrients"},{"issue":"9","key":"4655_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.mad.2008.04.008","volume":"129","author":"C Macchi","year":"2008","unstructured":"Macchi C, Molino-Lova R, Polcaro P, Guarducci L, Lauretani F, Cecchi F, et al. Higher Circulating levels of uric acid are prospectively associated with better muscle function in older persons. Mech Ageing Dev. 2008;129(9):522\u20137.","journal-title":"Mech Ageing Dev"},{"issue":"8","key":"4655_CR18","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3390\/nu12082390","volume":"12","author":"JP Floriano","year":"2020","unstructured":"Floriano JP, Nahas PC, de Branco FM, Dos Reis AS, Rossato LT, Santos HO, et al. Serum uric acid is positively associated with muscle mass and strength, but not with functional capacity, in kidney transplant patients. Nutrients. 2020;12(8):2390.","journal-title":"Nutrients"},{"issue":"6","key":"4655_CR19","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1016\/j.clnu.2020.12.043","volume":"40","author":"PC Nahas","year":"2021","unstructured":"Nahas PC, Rossato LT, de Branco FM, Azeredo CM, Rinaldi AE, de Oliveira EP. Serum uric acid is positively associated with muscle strength in older men and women: findings from NHANES 1999\u20132002. Clin Nutr. 2021;40(6):4386\u201393.","journal-title":"Clin Nutr"},{"issue":"10191","key":"4655_CR20","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA, Sarcopenia. Lancet. 2019;393(10191):2636\u201346.","journal-title":"Lancet"},{"issue":"4","key":"4655_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/ijms11041509","volume":"11","author":"SJ Meng","year":"2010","unstructured":"Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010;11(4):1509\u201326.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4655_CR22","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s00198-013-2377-7","volume":"24","author":"SH Ahn","year":"2013","unstructured":"Ahn SH, Lee SH, Kim BJ, Lim KH, Bae SJ, Kim EH, et al. Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int. 2013;24(12):2961\u201370.","journal-title":"Osteoporos Int"},{"issue":"4","key":"4655_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jfma.2012.11.014","volume":"114","author":"MH Shih","year":"2015","unstructured":"Shih MH, Lazo M, Liu SH, Bonekamp S, Hernaez R, Clark JM. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015;114(4):314\u201320.","journal-title":"J Formos Med Assoc"},{"issue":"8","key":"4655_CR24","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038\u201348.","journal-title":"Metabolism"},{"issue":"4","key":"4655_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","volume":"15","author":"D Kim","year":"2017","unstructured":"Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(4):474\u201385.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4655_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","volume":"21","author":"SM Grundy","year":"2006","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American heart Association\/National heart, Lung, and blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1\u20136.","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"4655_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/sj.ijo.0800772","volume":"23","author":"A Molarius","year":"1999","unstructured":"Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA project. Int J Obes Relat Metab Disord. 1999;23(2):116\u201325.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"3","key":"4655_CR28","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/j.ejrad.2013.12.011","volume":"83","author":"I Sporea","year":"2014","unstructured":"Sporea I, Bota S, Gradinaru-Ta\u015fc\u0103u O, \u015eirli R, Popescu A, Jurchi\u015f A. Which are the cut-off values of 2D-Shear wave elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering transient elastography (TE) as the reference method? Eur J Radiol. 2014;83(3):e118\u201322.","journal-title":"Eur J Radiol"},{"issue":"6","key":"4655_CR29","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver Diseases, American college of Gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005\u201323.","journal-title":"Hepatology"},{"issue":"3","key":"4655_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/1574887109666141216102231","volume":"9","author":"N Kobyliak","year":"2014","unstructured":"Kobyliak N, Abenavoli L. The role of liver biopsy to assess non-alcoholic fatty liver disease. Rev Recent Clin Trials. 2014;9(3):159\u201369.","journal-title":"Rev Recent Clin Trials"},{"issue":"2","key":"4655_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1665-2681(19)31021-X","volume":"11","author":"L Abenavoli","year":"2012","unstructured":"Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol. 2012;11(2):172\u20138.","journal-title":"Ann Hepatol"},{"issue":"1","key":"4655_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4292\/wjgpt.v7.i1.91","volume":"7","author":"PE Chang","year":"2016","unstructured":"Chang PE, Goh GB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther. 2016;7(1):91.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"1","key":"4655_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"4655_CR34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/jum.16048","volume":"42","author":"HN \u015eendur","year":"2023","unstructured":"\u015eendur HN, Cerit MN, Ibrahimkhanli N, \u015eendur AB, \u00d6zhan Oktar S. Interobserver variability in ultrasound-based liver fat quantification. J Ultrasound Med. 2023;42(4):833\u201341.","journal-title":"J Ultrasound Med"},{"issue":"4","key":"4655_CR35","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/1753-0407.12056","volume":"5","author":"X Gao","year":"2013","unstructured":"Gao X, Fan JG, Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the study group of liver and Metabolism, Chinese society of endocrinology. J Diabetes. 2013;5(4):406\u201315.","journal-title":"J Diabetes"},{"issue":"9","key":"4655_CR36","first-page":"600","volume":"55","author":"A Oral","year":"2019","unstructured":"Oral A, Sahin T, Turker F, Kocak E. Relationship between serum uric acid levels and nonalcoholic fatty liver disease in non-obese patients. Med (Kaunas). 2019;55(9):600.","journal-title":"Med (Kaunas)"},{"issue":"Suppl 1","key":"4655_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jgh.12271","volume":"28","author":"E Hashimoto","year":"2013","unstructured":"Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD\/NASH. J Gastroenterol Hepatol. 2013;28(Suppl 1):64\u201370.","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"4655_CR38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686\u201390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4655_CR39","first-page":"129","volume":"58","author":"P Socha","year":"2007","unstructured":"Socha P, Wierzbicka A, Neuhoff-Murawska J, W\u0142odarek D, Podle\u015bny J, Socha J. Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Rocz Panstw Zakl Hig. 2007;58(1):129\u201337.","journal-title":"Rocz Panstw Zakl Hig"},{"issue":"2","key":"4655_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C Li","year":"2013","unstructured":"Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"4655_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.metabol.2012.08.013","volume":"62","author":"JC Sirota","year":"2013","unstructured":"Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the united states: liver ultrasound data from the National health and nutrition examination survey. Metabolism. 2013;62(3):392\u20139.","journal-title":"Metabolism"},{"issue":"3","key":"4655_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3346\/jkms.2011.26.3.386","volume":"26","author":"IC Hwang","year":"2011","unstructured":"Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J Korean Med Sci. 2011;26(3):386\u201391.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"4655_CR43","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1136\/bmjgast-2020-000535","volume":"7","author":"MM Rahman","year":"2020","unstructured":"Rahman MM, Kibria MG, Begum H, Haque M, Sultana N, Akhter M, et al. Prevalence, risk factors and metabolic profile of non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. BMJ Open Gastroenterol. 2020;7(1):e000535.","journal-title":"BMJ Open Gastroenterol"},{"issue":"9","key":"4655_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1590\/1806-9282.20201005","volume":"67","author":"MA Kosekli","year":"2021","unstructured":"Kosekli MA, Kurtkulagii O, Kahveci G, Duman TT, Tel BM, Bilgin S, et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev Assoc Med Bras (1992). 2021;67(9):549\u201354.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"5","key":"4655_CR45","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/diagnostics11050787","volume":"11","author":"S Zenovia","year":"2021","unstructured":"Zenovia S, Stanciu C, Sfarti C, Singeap AM, Cojocariu C, Girleanu I, et al. Vibration-controlled transient elastography and controlled Attenuation parameter for the diagnosis of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Diagnostics (Basel). 2021;11(5):787.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"4655_CR46","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082\u201390.","journal-title":"Hepatology"},{"issue":"4","key":"4655_CR47","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1055\/s-0043-103952","volume":"38","author":"CF Dietrich","year":"2017","unstructured":"Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med. 2017;38(4):e16\u201347.","journal-title":"Ultraschall Med"},{"issue":"1","key":"4655_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-017-0531-5","volume":"16","author":"X Zheng","year":"2017","unstructured":"Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 2017;16(1):1\u20137.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"4655_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679\u201389.","journal-title":"Hepatology"},{"issue":"2","key":"4655_CR50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hep.25593","volume":"56","author":"D Kim","year":"2012","unstructured":"Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56(2):605\u201313.","journal-title":"Hepatology"},{"issue":"3","key":"4655_CR51","first-page":"7","volume":"4","author":"C Zhang","year":"2018","unstructured":"Zhang C, Song H, Yang L, Liu Y, Ji G. Does high level of uric acid lead to nonalcoholic fatty liver disease? GJ Dig Dis. 2018;4(3):7\u201314.","journal-title":"GJ Dig Dis"},{"key":"4655_CR52","doi-asserted-by":"publisher","first-page":"2780637","DOI":"10.1155\/2016\/2862173","volume":"2016","author":"J Yu","year":"2016","unstructured":"Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract. 2016;2016:2780637.","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"4655_CR53","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/MEG.0000000000000865","volume":"29","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich V, Ahuja W, Wijarnpreecha K, Ungprasert P. Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(6):694\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"4655_CR54","first-page":"2749","volume":"10","author":"H Wang","year":"2018","unstructured":"Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am J Transl Res. 2018;10(9):2749\u201364.","journal-title":"Am J Transl Res"},{"issue":"1","key":"4655_CR55","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.1038\/s41598-020-64884-7","volume":"10","author":"N Ali","year":"2020","unstructured":"Ali N, Miah R, Hasan M, Barman Z, Mou AD, Hafsa JM, et al. Association between serum uric acid and metabolic syndrome: a cross-sectional study in Bangladeshi adults. Sci Rep. 2020;10(1):7841.","journal-title":"Sci Rep"},{"issue":"7","key":"4655_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2036.2011.04788.x","volume":"34","author":"S Petta","year":"2011","unstructured":"Petta S, Camm\u00e0 C, Cabibi D, Di Marco V, Crax\u00ec A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(7):757\u201366.","journal-title":"Aliment Pharmacol Ther"},{"key":"4655_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fendo.2020.00179","volume":"11","author":"F Wei","year":"2020","unstructured":"Wei F, Li J, Chen C, Zhang K, Cao L, Wang X, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study. Front Endocrinol (Lausanne). 2020;11:179.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04655-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04655-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04655-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:28:45Z","timestamp":1781641725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04655-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4655"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04655-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol and execution adhere to the ethical standards outlined in the 1975 Declaration of Helsinki. All participants or their legal guardians were apprised of the study\u2019s goals and potential outcomes, and data confidentiality was assured. The study\u2019s approval came from the Faculty of Medicine\u2019s ethical committee at Minia University with approval number (327\/03\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}